Why have I plateaued on Wegovy — and what actually happens next

The biggest misconception: that a plateau means Wegovy isn't working for you

This is the one worth gently setting aside first. The idea that a stalling scale means the medicine has failed is understandable (it feels that way) but it conflates two things that are not the same. Wegovy continues to suppress appetite, slow gastric emptying, and support the hormonal environment for weight loss even when the number on the scales isn't shifting. What changes is the size of the energy deficit, not the presence of the drug's effect.

Your body is not passive during weight loss. As body weight falls, your basal metabolic rate falls with it, you need fewer calories at 85 kg than you did at 100 kg, even doing the same things. At the same time, adaptive thermogenesis can reduce energy expenditure beyond what weight alone would predict. The gap between calories in and calories burned narrows. The result is a wegovy plateau that is metabolically logical, however frustrating it feels at 10 weeks of no progress.

The STEP 1 trial, published in the New England Journal of Medicine, enrolled 1,961 adults and found an average body-weight reduction of around 15% over 68 weeks at 2.4 mg semaglutide. That average masks the shape of the curve: loss tends to be fastest in the first few months and slows considerably by mid-treatment in most participants. Seeing a plateau at week 20 or 24 is consistent with what was observed in clinical trials, not a departure from them.

Worth knowing: a true non-response (less than 5% weight loss after six months on the maintenance dose) is the clinical threshold NICE uses to consider whether continuing treatment is appropriate. If you are plateaued on Wegovy mid-treatment, that is almost never the same as a true non-response.

What actually causes the stall: four things worth examining

Once the biology is understood, it's useful to look at four practical contributors that a prescriber will typically ask about before recommending any change.

Protein and hydration are frequently underestimated. Semaglutide reduces appetite substantially, which is its mechanism, but a smaller appetite can mean inadequate protein intake, which accelerates the loss of lean muscle mass rather than fat. Less muscle means a lower resting metabolic rate, which compounds the plateau. The NHS guidance on semaglutide for weight management notes the importance of maintaining a balanced diet alongside treatment.

Physical activity relative to body weight matters too. You weigh less than you did, so the same 30-minute walk burns fewer calories. That's not a reason to be disheartened; it means the activity level that produced a deficit earlier in treatment now needs to be sustained or gently increased to preserve it. Strength training specifically can help maintain muscle during active weight loss, which supports a higher resting metabolic rate over time.

Dose position is a third variable. Semaglutide is titrated from 0.25 mg upward to a 2.4 mg maintenance dose over several months. If you are still at an intermediate dose, plateauing on Wegovy may simply reflect that the full therapeutic dose hasn't been reached yet. A prescriber is the right person to assess where you are in that sequence and whether progression is appropriate.

Injection technique and consistency are worth reviewing too. Semaglutide is a subcutaneous injection into the abdomen, thigh, or upper arm. If the injection site isn't rotated, or if the technique has drifted, absorption can be affected. Missed doses (even occasional ones) can reduce the medicine's steadying effect on appetite. This is more common than people expect and easy to correct once identified.

When to take a plateau to a prescriber rather than wait it out

Not every plateau needs an intervention. Some resolve within a few weeks as the body re-adjusts. But there are situations where a prescriber's view adds real value rather than simply waiting.

If the plateau has persisted for more than eight to twelve weeks with no movement at all, a clinical review is reasonable. A prescriber can look at where you are in the dose schedule, check whether six months on the maintenance dose without 5% loss applies here, and consider whether the current treatment remains the right fit. Our prescribers at the nume clinical team review this kind of question regularly, it is a clinical conversation, not an administrative one.

If you are also experiencing new symptoms (persistent nausea that hasn't settled, significant fatigue, or anything that feels different from the early-treatment GI effects) those are separate reasons to speak to a prescriber rather than attribute everything to the plateau.

People sometimes ask at this point whether switching from Wegovy to tirzepatide (Mounjaro) is an option. It is a question a prescriber can answer in the context of your full history. The SURMOUNT-5 head-to-head trial published in 2025 found tirzepatide produced greater average weight reduction than semaglutide 2.4 mg over 72 weeks, and a full overview of how Wegovy and tirzepatide compare covers the evidence in more detail. That said, switching medicines is a clinical decision, not a response to impatience.

For a broader sense of what weight loss on semaglutide typically looks like over the full treatment period, the typical weight loss on Wegovy page sets out the trial data and what realistic expectations look like at different stages. And if you are wondering whether the cost of ongoing treatment is a factor in your decision-making, the Wegovy pricing page sets out what private treatment involves transparently.

The short version: a plateau is a signal to look more carefully, not to stop. If you'd like a prescriber to review your current position, you can speak to our prescribers through a free consultation, a real clinician reads your case, not a chatbot.